menu
    • menu
    [{"orgOrder":0,"company":"E2Bio Life Sciences","sponsor":"Hematology Center after Prof. R. Yeolyan","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Benzydamine Hydrochloride","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"E2Bio Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"E2Bio Life Sciences \/ Hematology Center after Prof. R. Yeolyan","highestDevelopmentStatusID":"7","companyTruncated":"E2Bio Life Sciences \/ Hematology Center after Prof. R. Yeolyan"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Benzydamine Hydrochloride","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Angelini Pharma \/ PPD","highestDevelopmentStatusID":"11","companyTruncated":"Angelini Pharma \/ PPD"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Zak-Pharma Dienstleistung Ges.m.b.H.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Benzydamine Hydrochloride","moa":"Cyclooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Angelini Pharma \/ Zak-Pharma Dienstleistung Ges.m.b.H.","highestDevelopmentStatusID":"11","companyTruncated":"Angelini Pharma \/ Zak-Pharma Dienstleistung Ges.m.b.H."},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Cross Research S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Benzydamine Hydrochloride","moa":"Cyclooxygenase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angelini Pharma \/ Cross Research S.A.","highestDevelopmentStatusID":"6","companyTruncated":"Angelini Pharma \/ Cross Research S.A."}]

    Find Clinical Drug Pipeline Developments & Deals for Benzydamine Hydrochloride

    Menu

    Benzydamine Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Angelini Pharma

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benzydamine Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Cross Research S.A.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Palatability Study of Five Formulations of Benzydamine HCl Lozenges

                            Details : Benzydamine HCl is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Anemia, Sickle Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 30, 2025

                            Lead Product(s) : Benzydamine Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Cross Research S.A.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            E2Bio Life Sciences

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            E2Bio Life Sciences

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benzydamine Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hematology Center after Prof. R. Yeolyan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study for the Prevention of Oral Mucositis (SPOM)

                            Details : Benzydamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stomatitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 21, 2022

                            Lead Product(s) : Benzydamine Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hematology Center after Prof. R. Yeolyan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Angelini Pharma

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benzydamine Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase IV

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Benzydamine Oromucosal Solution in Oral Mucositis (BOOM)

                            Details : Benzydamine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Mucositis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 24, 2021

                            Lead Product(s) : Benzydamine Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase IV

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Angelini Pharma

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benzydamine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Zak-Pharma Dienstleistung Ges.m.b.H.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Benzydamine in Sore Throat Pain Relief (BePaiR Study)

                            Details : Benzydamine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pharyngitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 28, 2021

                            Lead Product(s) : Benzydamine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Zak-Pharma Dienstleistung Ges.m.b.H.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth